Accessibility StatementSkip Navigation PLYMOUTH MEETING, Pa., Oct. 21, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced results from a Phase 1 proof-of-concept trial evaluating DMAbs for COVID-19 were published online in Nature Medicine under the title "Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodie ...